| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemorrhagic Septicemia, Viral | D031941 | 1 associated lipids |
| Persian Gulf Syndrome | D018923 | 1 associated lipids |
| Steatorrhea | D045602 | 2 associated lipids |
| Ossification, Heterotopic | D009999 | 2 associated lipids |
| Fasciitis | D005208 | 2 associated lipids |
| Pneumonia, Lipid | D011017 | 2 associated lipids |
| Gallbladder Diseases | D005705 | 3 associated lipids |
| Exostoses, Multiple Hereditary | D005097 | 3 associated lipids |
| Hyperlipoproteinemia Type III | D006952 | 4 associated lipids |
| Coronavirus Infections | D018352 | 4 associated lipids |
(e,e,e,e)-squalene
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
Cross Reference
Introduction
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with (e,e,e,e)-squalene?
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
PubChem Associated disorders and diseases
What pathways are associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with (e,e,e,e)-squalene?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with (e,e,e,e)-squalene?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with (e,e,e,e)-squalene
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Li RC et al. | [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly]. | 2008 | Zhonghua Liu Xing Bing Xue Za Zhi | pmid:19040034 |
| Liu Y et al. | [Researches on influence of squalene synthase gene polymorphism on catalytic efficiency of its encode enzyme in Glycyrrhiza uralensis]. | 2012 | Zhongguo Zhong Yao Za Zhi | pmid:23627178 |
| de la Puerta R et al. | Effect of minor components of virgin olive oil on topical antiinflammatory assays. | 2000 Sep-Oct | Z. Naturforsch., C, J. Biosci. | pmid:11098836 |
| Kopena R et al. | Lipophilic compounds from the femoral gland secretions of male Hungarian green lizards, Lacerta viridis. | 2009 May-Jun | Z. Naturforsch., C, J. Biosci. | pmid:19678551 |
| Gloor M | [The significance of physiological and biochemical deviations from the norm on the skin surface for infectious skin diseases (proceedings)]. | 1976 | Z. Hautkr. | pmid:13544 |
| Kipping D | [Observations on skin surface fats]. | 1965 | Z Haut Geschlechtskr | pmid:5860995 |
| Sondergaard E et al. | Alimentary production of gallstones in hamsters. 28. Influence of isomerized squalene on gallstone production. | 1974 | Z Ernahrungswiss | pmid:4450595 |
| Dam H et al. | Alimentary production of gallstones in hamsters. 27. Influence of supplementation of the gallstone producing diet with squalene, cholesterol, certain other sterols, fish oil fatty acid ethyl esters, and modification of the basal diet on gallstone production and levels of cholesterol in serum and liver. | 1974 | Z Ernahrungswiss | pmid:4615449 |
| Zhang Y et al. | [Chemical constituents from the mangrove plant Ceriops tagal]. | 2005 | Yao Xue Xue Bao | pmid:16408813 |
| Ikekawa T et al. | [Studies on antitumor activity of squalene and its related compounds]. | 1986 | Yakugaku Zasshi | pmid:3772729 |
| Tsai TF | MF59 adjuvanted seasonal and pandemic influenza vaccines. | 2011 | Yakugaku Zasshi | pmid:22129867 |
| Abe I | [Engineering of squalene cyclizing enzymes]. | 2008 | Yakugaku Zasshi | pmid:18670176 |
| Hu JJ et al. | [Antibody production and its neutralization of Abeta42's cytoxicity in BALB/c mice induced by Abeta42 and its subunit vaccines]. | 2004 | Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi | pmid:15191720 |
| Richter E et al. | Stimulation of the faecal excretion of 2,4,5,2',4',5'-hexachlorobiphenyl in rats by squalane. | 1983 | Xenobiotica | pmid:6415933 |
| Global Advisory Committee on Vaccine Safety, 6-7 June 2006. | 2006 | Wkly. Epidemiol. Rec. | pmid:16841398 | |
| Lynen F | [The biochemical basis of the biosynthesis of cholesterol and fatty acids]. | 1966 | Wien. Klin. Wochenschr. | pmid:4296920 |
| Bakalar B et al. | Changes in cholesterol and its precursors during the first days after major trauma. | 2003 | Wien. Klin. Wochenschr. | pmid:14743581 |
| Zhao M et al. | [Research progress on the squalene synthase]. | 2003 | Wei Sheng Wu Xue Bao | pmid:16281569 |
| Kozlov VG and Viktorova EG | [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. | 2011 Mar-Apr | Vopr. Virusol. | pmid:21545042 |
| Palamarchuk VI et al. | [Content of squalene and sterols in tissues of the hemopoietic system in normal rats and in experimental leukemia]. | 1983 May-Jun | Vopr. Med. Khim. | pmid:6880121 |
| PokrovskiÄ AA et al. | [Method of isolating, identifying and quantitatively determining alkanes, cycloalkanes, monocyclic arenes and squalene in animal organs and tissues]. | 1978 Sep-Oct | Vopr Pitan | pmid:716335 |
| Markelova VF and Levachev MM | [Inclusion of C14-acetate in cholesterol and tissue squalene of rats in choline-protein deficiency]. | 1967 Nov-Dec | Vopr Pitan | pmid:5610866 |
| Gonor KV et al. | [The influence of a diet with including amaranth oil on antioxidant and immune status in patients with ischemic heart disease and hyperlipoproteidemia]. | 2006 | Vopr Pitan | pmid:17313043 |
| Gonor KV et al. | [The influence of diet with including amaranth oil on lipid metabolism in patients with ischemic heart disease and hyperlipoproteidemia]. | 2006 | Vopr Pitan | pmid:16862949 |
| Kulakova SN et al. | [Amaranths oil: peculiarities of chemical composition and influence on lipid metabolism by rats]. | 2006 | Vopr Pitan | pmid:16862953 |
| Zadák Z et al. | [The role of cholesterol and intermediary metabolites of its synthesis in intensive care and parenteral nutrition]. | 2000 | Vnitr Lek | pmid:15637893 |
| Clouse SD | Brassinosteroids. Plant counterparts to animal steroid hormones? | 2002 | Vitam. Horm. | pmid:12481548 |
| Stephenson I et al. | Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. | 2004 | Virus Res. | pmid:15163495 |
| Burke B et al. | Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. | 2009 | Virology | pmid:19249806 |
| Drulak MW et al. | Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin. | 2000 | Viral Immunol. | pmid:10733168 |
| Marshall BC and Adler SP | Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). | 2003 | Viral Immunol. | pmid:14733736 |
| Heinemann L et al. | Effective induction of type 1 helper IgG2a and cytotoxic T-cell responses in mice following immunization with human papillomavirus type 16 E2 in MF59. | 2008 | Viral Immunol. | pmid:18476769 |
| Vinay TN et al. | Toxicity and dose determination of quillaja saponin, aluminum hydroxide and squalene in olive flounder (Paralichthys olivaceus). | 2014 | Vet. Immunol. Immunopathol. | pmid:23570990 |
| Ott G et al. | Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. | 1995 | Vaccine | pmid:8578842 |
| Higgins DA et al. | MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. | 1996 | Vaccine | pmid:8782343 |
| Cataldo DM and Van Nest G | The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. | 1997 | Vaccine | pmid:9364672 |
| Hilgers LA et al. | A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. | 1994 | Vaccine | pmid:8085385 |
| Hilgers LA et al. | A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. | 1994 | Vaccine | pmid:8085386 |
| Byars NE et al. | Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. | 1994 | Vaccine | pmid:8165851 |
| Singh M et al. | A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. | 1998 | Vaccine | pmid:9795387 |
| Barchfeld GL et al. | The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. | 1999 | Vaccine | pmid:10067675 |
| Dupuis M et al. | Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. | 1999 | Vaccine | pmid:10519932 |
| De Donato S et al. | Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. | 1999 | Vaccine | pmid:10462245 |
| Minutello M et al. | Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. | 1999 | Vaccine | pmid:9987141 |
| Hilgers LA et al. | Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. | 1999 | Vaccine | pmid:9987157 |
| Podda A | The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. | 2001 | Vaccine | pmid:11257408 |
| Greer CE et al. | The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles. | 2000 | Vaccine | pmid:11137233 |
| Skeiky YA et al. | Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. | 2002 | Vaccine | pmid:12213399 |
| Stephenson I et al. | Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. | 2003 | Vaccine | pmid:12639491 |
| Iorio AM et al. | Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. | 2003 | Vaccine | pmid:12922092 |
| Romera SA et al. | Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle. | 2000 | Vaccine | pmid:10924795 |
| Süli J et al. | Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. | 2004 | Vaccine | pmid:15308373 |
| BenÃsek Z et al. | Experimental squalene adjuvant. II. Harmlessness and local reactogenity. | 2004 | Vaccine | pmid:15308374 |
| Madhun AS et al. | An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. | 2010 | Vaccine | pmid:21034828 |
| Garcia-Sicilia J et al. | Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. | 2011 | Vaccine | pmid:21504774 |
| Calabro S et al. | Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. | 2011 | Vaccine | pmid:21215831 |
| Javelle E et al. | Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. | 2011 | Vaccine | pmid:21172376 |
| Esposito S et al. | Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. | 2011 | Vaccine | pmid:21199699 |
| Esposito S et al. | Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. | 2010 | Vaccine | pmid:20888873 |
| Tritto E et al. | Mechanism of action of licensed vaccine adjuvants. | 2009 | Vaccine | pmid:19200813 |
| Ansaldi F et al. | Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. | 2009 | Vaccine | pmid:19200846 |
| Pellegrini M et al. | MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. | 2009 | Vaccine | pmid:19751689 |
| Forrest HL et al. | Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. | 2009 | Vaccine | pmid:19406182 |
| Camilloni B et al. | Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. | 2009 | Vaccine | pmid:19410623 |
| Phillips CJ et al. | Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. | 2009 | Vaccine | pmid:19379786 |
| Ansaldi F et al. | Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. | 2010 | Vaccine | pmid:20433807 |
| Carmona A et al. | Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. | 2010 | Vaccine | pmid:20600478 |
| Frey SE et al. | Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. | 2010 | Vaccine | pmid:20619382 |
| Camilloni B et al. | An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. | 2010 | Vaccine | pmid:20846530 |
| Fabbiani M et al. | Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. | 2011 | Vaccine | pmid:21349364 |
| Dell'Era L et al. | Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. | 2012 | Vaccine | pmid:22138210 |
| Okike IO et al. | The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. | 2011 | Vaccine | pmid:21742005 |
| Radosević K et al. | Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. | 2008 | Vaccine | pmid:18514980 |
| Brito LA et al. | An alternative renewable source of squalene for use in emulsion adjuvants. | 2011 | Vaccine | pmid:21723355 |
| Puig-Barberà J et al. | Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. | 2007 | Vaccine | pmid:17889411 |
| Guillon C et al. | Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. | 2007 | Vaccine | pmid:17904700 |
| Baldo V et al. | MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. | 2007 | Vaccine | pmid:17383057 |
| Wack A et al. | Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. | 2008 | Vaccine | pmid:18162266 |
| Bråve A et al. | Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. | 2007 | Vaccine | pmid:17707956 |
| Ansaldi F et al. | Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. | 2008 | Vaccine | pmid:18294741 |
| de Roux A et al. | Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. | 2006 | Vaccine | pmid:16288937 |
| O'Hagan DT et al. | Cationic microparticles are a potent delivery system for a HCV DNA vaccine. | 2004 | Vaccine | pmid:15542189 |
| Schultze V et al. | Safety of MF59 adjuvant. | 2008 | Vaccine | pmid:18462843 |
| Faenzi E et al. | One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. | 2012 | Vaccine | pmid:22521851 |
| Hatz C et al. | A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. | 2012 | Vaccine | pmid:22626675 |
| Candela S et al. | An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one. | 2013 | Vaccine | pmid:22766247 |
| O'Hagan DT et al. | The mechanism of action of MF59 - an innately attractive adjuvant formulation. | 2012 | Vaccine | pmid:22682289 |
| Yu S et al. | Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. | 2012 | Vaccine | pmid:22709954 |
| Dey AK et al. | Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. | 2012 | Vaccine | pmid:22366638 |
| Reynales H et al. | A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. | 2012 | Vaccine | pmid:22902681 |
| Ventura R et al. | Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. | 2013 | Vaccine | pmid:22884665 |
| Moro ML et al. | A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. | 2013 | Vaccine | pmid:22885015 |
| Chandramouli S et al. | Generation of a parvovirus B19 vaccine candidate. | 2013 | Vaccine | pmid:23827313 |
| Yang WH et al. | Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. | 2013 | Vaccine | pmid:23856331 |
| Calabro S et al. | The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. | 2013 | Vaccine | pmid:23684834 |
| Tetsutani K and Ishii KJ | Adjuvants in influenza vaccines. | 2012 | Vaccine | pmid:23084848 |
| Nielsen AB et al. | Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. | 2012 | Vaccine | pmid:23036498 |
| Segura-Velázquez R et al. | Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant. | 2013 | Vaccine | pmid:23746458 |
| Puig-Barberà J et al. | MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. | 2013 | Vaccine | pmid:23731629 |
| Rouleau I et al. | Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. | 2013 | Vaccine | pmid:24144473 |